archive-fr.com » FR » I » IT-INITIATIVE.FR

Total: 133

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Investment Strategy
    of Inserm Transfert Initiative InotremRaises 18 million to Develop Innovative Sepsis Treatmentsin a Series A Financing Co led by Edmon de Rothschild Investment Partners and Sofinnova Partners Axilum Robotics announces Health Canada licence for TMS Robot the world s first robot developed specifically for Transcranial Magnetic Stimulation TMS We syndicate with financial partners who share our strategy teaming up with scientific founders to foster innovation and entrepreneurship Prior to investing

    Original URL path: http://www.it-initiative.fr/investment/our-seed-investment-strategy (2015-10-11)
    Open archived version from archive


  • Investment Process
    of Inserm Transfert Initiative InotremRaises 18 million to Develop Innovative Sepsis Treatmentsin a Series A Financing Co led by Edmon de Rothschild Investment Partners and Sofinnova Partners Axilum Robotics announces Health Canada licence for TMS Robot the world s first robot developed specifically for Transcranial Magnetic Stimulation TMS Due diligence processes are partnered with a network of key opinion leaders and entrepreneurs from academic research industry and venture capital Our

    Original URL path: http://www.it-initiative.fr/investment/investment-process (2015-10-11)
    Open archived version from archive

  • Portfolio
    resolution imaging instruments for the worldwide R D teams of the Life Sciences and Healthcare Bioaxial breakthrough technology enables enhanced imaging capabilities required for advanced research Bioaxial offers a range of improved imaging solutions integrated to confocal microscopes platforms This flexible offering enables the user to easily upgrade existing confocal microscopes for improved resolution website DNA Therapeutics Novel approach using DNA fragments siDNA mimicking DNA damage By jamming DNA damage sensing and signaling siDNA can increase the efficacy of radiotherapy and chemotherapy without adding any cytotoxic effect The lead compound DT01 is currently in phase I IIa in melanoma website Effimune Discovery and the development of novel immunomodulators and more specifically modulatory drugs for the co stimulation of T cells The lead antibody FR104 is a CD28 antagonist under regulatory preclinical development showing promising proof of concept in the protection of graft rejections website Eyevensys Novel solutions for sustainable intraocular production of therapeutic proteins website Genoscreen Services related to detection and characterization of genetic variants sequencing and genotyping SNPs microsatellites website Hemarina Development of a haemoglobin oxygen carrier extracted and purified from a marine organism Hemarina positions itself as an R D company focused on oxygen carrier molecules that have therapeutic and industrial applications The lead compound HEMO2Life will enter clinical development based on promising proof of concept results as an additive to organ preservation solutions website Mutabilis Novel generation of anti retroviral molecules Instead of targeting the inhibition of the catalytic activity of viral enzymes the lead compound targets host virus protein protein interactions ex cellvir website Neorphys Novel analgesic drug candidates with lower side effects especially with regard to gastro intestinal transit The lead compound NEO1509 is under regulatory preclinical development The first indication will be postoperative pain website Neurokin Novel generation of CDK inhibitors as neuroprotectants for

    Original URL path: http://www.it-initiative.fr/portfolio (2015-10-11)
    Open archived version from archive

  • Portfolio list
    high resolution imaging instruments for the worldwide R D teams of the Life Sciences and Healthcare Bioaxial breakthrough technology enables enhanced imaging capabilities required for advanced research Bioaxial offers a range of improved imaging solutions integrated to confocal microscopes platforms This flexible offering enables the user to easily upgrade existing confocal microscopes for improved resolution website DNA Therapeutics Novel approach using DNA fragments siDNA mimicking DNA damage By jamming DNA damage sensing and signaling siDNA can increase the efficacy of radiotherapy and chemotherapy without adding any cytotoxic effect The lead compound DT01 is currently in phase I IIa in melanoma website Effimune Discovery and the development of novel immunomodulators and more specifically modulatory drugs for the co stimulation of T cells The lead antibody FR104 is a CD28 antagonist under regulatory preclinical development showing promising proof of concept in the protection of graft rejections website Eyevensys Novel solutions for sustainable intraocular production of therapeutic proteins website Genoscreen Services related to detection and characterization of genetic variants sequencing and genotyping SNPs microsatellites website Hemarina Development of a haemoglobin oxygen carrier extracted and purified from a marine organism Hemarina positions itself as an R D company focused on oxygen carrier molecules that have therapeutic and industrial applications The lead compound HEMO2Life will enter clinical development based on promising proof of concept results as an additive to organ preservation solutions website Mutabilis Novel generation of anti retroviral molecules Instead of targeting the inhibition of the catalytic activity of viral enzymes the lead compound targets host virus protein protein interactions ex cellvir website Neorphys Novel analgesic drug candidates with lower side effects especially with regard to gastro intestinal transit The lead compound NEO1509 is under regulatory preclinical development The first indication will be postoperative pain website Neurokin Novel generation of CDK inhibitors as neuroprotectants

    Original URL path: http://www.it-initiative.fr/portfolio/portofolio-list (2015-10-11)
    Open archived version from archive

  • Recent Investments
    Develop Innovative Sepsis Treatmentsin a Series A Financing Co led by Edmon de Rothschild Investment Partners and Sofinnova Partners Axilum Robotics announces Health Canada licence for TMS Robot the world s first robot developed specifically for Transcranial Magnetic Stimulation TMS Novel robotized solutions to assist Health Care Professionals with medical procedures The first product is a robot to assist psychiatrists and neurologists in delivering Transcranial Magnetic Stimulation TMS Beyond its participation in our capital ITI s expertise is a key asset for the success of our company and in particular our international development Michel Berg CEO Bioaxial is developing and providing high resolution imaging instruments for the worldwide R D teams of the Life Sciences and Healthcare Beyond its participation in our capital ITI s expertise is a key asset for the success of our company and in particular our international development This is a vote of confidence in the Bioaxial team and its technology Philippe BRAITBART CEO Novel solutions for sustainable intraocular production of therapeutic proteins We are truly grateful for ITI s triggering our partnership with Boehringer Ingelheim Venture Fund as a new shareholder of Eyevensys Ivan Cohen Tanugi CEO Novel compounds for the treatment of inner ear

    Original URL path: http://www.it-initiative.fr/portfolio/recent-investments (2015-10-11)
    Open archived version from archive

  • Exits Portfolio
    to raise 1 3 million to finance the development of a treatment of cannabis addiction Cécile Tharaud appointed as President and Managing Partner of Inserm Transfert Initiative InotremRaises 18 million to Develop Innovative Sepsis Treatmentsin a Series A Financing Co led by Edmon de Rothschild Investment Partners and Sofinnova Partners Axilum Robotics announces Health Canada licence for TMS Robot the world s first robot developed specifically for Transcranial Magnetic Stimulation

    Original URL path: http://www.it-initiative.fr/portfolio/exits-portfolio (2015-10-11)
    Open archived version from archive

  • People
    CEO Inserm Transfert Initiative Dr François Thomas is President of Inserm Transfert Initiative ITI He is a medical oncologist and a former assistant professor at the Gustave Roussy Institute He also holds an MBA from MIT Boston François Thomas was successively vice president VP for clinical development of Ipsen managing partner of Bioserve Ltd VP in charge of pharmacogenomic programs and licensing at Genset partner in the venture capital firm Atlas Venture in charge of healthcare banking activities at Bryan Garnier and president of Cytheris His professional activity over the last 15 years has been dedicated to the creation and development of biotech companies in Europe Office Manager Before joining Inserm Transfert Initiative Nelly Picardat worked since 2007 within the presidency and the head office of different start ups in biotechnology and trade medicine Nelly Picardat worked as executive assistant in the department on Prevention Screening and Information at INCa Institut National du Cancer and LNCC Ligue Nationale contre le Cancer She graduated from ISEFAC ISEG Group BTS Management Assistant and has a diploma of the economic and social baccalaureat Advisor D r Jean Jacques Garaud is a senior executive with a broad experience in Research and Development in the

    Original URL path: http://www.it-initiative.fr/people (2015-10-11)
    Open archived version from archive

  • Team
    TMS CEO Inserm Transfert Initiative Dr François Thomas is President of Inserm Transfert Initiative ITI He is a medical oncologist and a former assistant professor at the Gustave Roussy Institute He also holds an MBA from MIT Boston François Thomas was successively vice president VP for clinical development of Ipsen managing partner of Bioserve Ltd VP in charge of pharmacogenomic programs and licensing at Genset partner in the venture capital firm Atlas Venture in charge of healthcare banking activities at Bryan Garnier and president of Cytheris His professional activity over the last 15 years has been dedicated to the creation and development of biotech companies in Europe Office Manager Before joining Inserm Transfert Initiative Nelly Picardat worked since 2007 within the presidency and the head office of different start ups in biotechnology and trade medicine Nelly Picardat worked as executive assistant in the department on Prevention Screening and Information at INCa Institut National du Cancer and LNCC Ligue Nationale contre le Cancer She graduated from ISEFAC ISEG Group BTS Management Assistant and has a diploma of the economic and social baccalaureat Advisor D r Jean Jacques Garaud is a senior executive with a broad experience in Research and Development in

    Original URL path: http://www.it-initiative.fr/people/team (2015-10-11)
    Open archived version from archive